ethyl 4-(tert-butoxycarbonylamino)cyclohexanecarboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-(tert-butoxycarbonylamino)cyclohexanecarboxylate
• 英文别名: ethyl 4-t-butoxycarbonylaminocyclohexanecarboxylate；ethyl 4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylate
• 化学式: C₁₄H₂₅NO₄
• 分子量: 271.357
• InChiKey: KDAADPYICYRBEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-(tert-butoxycarbonylamino)cyclohexanecarboxylate 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以94%的产率得到BOC-4-氨基苄醇
  参考文献：
  名称：

  Design and Synthesis of Non-peptidic Inhibitors for the Syk C-Terminal SH2 Domain Based on Structure-Based In-Silico Screening

  摘要：

  Structure-based in-silico screening was carried out for the Syk C-terminal SH2 domain. Fragments that could interact with the pY or pY+1 pockets were selected by our in-silico screening. After tethering two fragments bound to these pockets, we have designed and synthesized new compounds that show favorable interaction with the pY+3 pocket. One such compound, having a cyclohexylmalonic acid moiety identified as a novel potent phosphotyrosyl mimetic, exhibited an affinity comparable to that of the monophosphorylated ligand peptide.

  DOI：

  10.1021/jm010313k
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 苯佐卡因 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 96.0h， 以83%的产率得到ethyl 4-(tert-butoxycarbonylamino)cyclohexanecarboxylate
  参考文献：
  名称：

  Design and Synthesis of Non-peptidic Inhibitors for the Syk C-Terminal SH2 Domain Based on Structure-Based In-Silico Screening

  摘要：

  Structure-based in-silico screening was carried out for the Syk C-terminal SH2 domain. Fragments that could interact with the pY or pY+1 pockets were selected by our in-silico screening. After tethering two fragments bound to these pockets, we have designed and synthesized new compounds that show favorable interaction with the pY+3 pocket. One such compound, having a cyclohexylmalonic acid moiety identified as a novel potent phosphotyrosyl mimetic, exhibited an affinity comparable to that of the monophosphorylated ligand peptide.

  DOI：

  10.1021/jm010313k

文献信息

• [EN] BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS BENZIMIDAZOLE ET AZABENZIMIDAZOLE QUI INHIBENT LA KINASE DES LYMPHOMES ANAPLASIQUES
  申请人：AMGEN INC

  公开号：WO2012018668A1

  公开（公告）日：2012-02-09

  Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

  公式（I）的化合物是有用的间变性淋巴瘤激酶抑制剂。公式（I）的化合物具有以下结构：其中变量的定义如下。
• [EN] SSTR5 ANTAGONISTS<br/>[FR] ANTAGONISTES DE SSTR5
  申请人：KALLYOPE INC

  公开号：WO2021113368A1

  公开（公告）日：2021-06-10

  This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

  这项披露至少部分针对SSTR5拮抗剂，用于治疗涉及肠脑轴的疾病或疾病。在某些实施例中，SSTR5拮抗剂是肠限制性化合物。在某些实施例中，该疾病或疾病是代谢性疾病，如糖尿病、肥胖症、非酒精性脂肪肝炎（NASH）或营养紊乱，如短肠综合征。
• [EN] ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'ARYL SULFONES COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ZALICUS PHARMACEUTICALS LTD

  公开号：WO2011035159A1

  公开（公告）日：2011-03-24

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的N型和/或T型钙通道活性。具体来说，包含芳基磺酰基衍生物的一系列化合物被列举为示例，如公式（I）所示。
• Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative
  申请人：Seki Masahiko

  公开号：US20060173188A1

  公开（公告）日：2006-08-03

  The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: —N═ or —CH═; R 1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R 3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of activated blood coagulation factor X.

  本发明提供了一种制备式[I]化合物的方法：其中X是公式：—N═或—CH═ 的基团；R1是氢原子、卤素原子、低烷基、低烷氧基、氰基或者是可选择被低烷基取代的氨基基团；环A是含有氮杂环基团；环B是可选择被取代的苯环或者是可选择被取代的吡啶环；R3是氢原子或者是低烷基，或者其药学上可接受的盐，该化合物是一种活化血凝因子X抑制剂。
• PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE
  申请人：SEKI Masahiko

  公开号：US20090023918A1

  公开（公告）日：2009-01-22

  The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: —N═ or —CH═; R 1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R 3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of activated blood coagulation factor X.

  本发明提供了一种制备式[I]化合物的方法：其中X是公式：—N═或—CH═的基团；R1是氢原子、卤素原子、低碳基、低烷氧基、氰基或者是经低碳基取代的氨基基团；环A是含氮杂环基团；环B是可选取代的苯环或者是可选取代的吡啶环；R3是氢原子或者是低碳基，或者是其药学上可接受的盐，其可用作活化的血凝因子X的抑制剂。